Jubilant Pharmova Announces ₹800 Crore Debt Issuance Plan

The Board of Jubilant Pharmova has approved raising up to ₹800 crore via NCDs, while simultaneously seeking shareholder approval for an aggregate debt limit of ₹2,500 crore.

Reader Takeaway: The move signals active capital management; however, increased debt levels will necessitate monitoring of future interest cost burdens.

What just happened

In a board meeting held on October 12, 2026, Jubilant Pharmova Limited finalized plans to raise funds through a private placement of non-convertible debentures (NCDs). The board approved an issuance of up to 80,000 NCDs with a face value of ₹1,00,000 each. The company also initiated a special resolution process to seek shareholder consent to maintain a total outstanding debt amount of up to ₹2,500 crore for the next twelve months.

Why this matters

The ₹800 crore NCD issuance is designed to support the company's capital requirements. By securing an enabling resolution for a higher ₹2,500 crore aggregate limit, management gains the agility to tap into debt markets as business opportunities arise or liquidity needs shift. This approach reduces the need for repeated board meetings for routine debt raising over the next year.

What changes now

The company will proceed with the NCD issuance process, with the final interest rates and coupon payments to be determined through a bidding process. The NCDs are proposed to be listed on the BSE, providing transparency for retail and institutional investors. Shareholders will soon vote on the broader ₹2,500 crore debt ceiling proposal.

What to track next

Investors should look for official announcements regarding the final coupon rates discovered during the bidding process and the actual utilization of the raised funds. Monitoring the company’s debt-to-equity ratio in future quarterly filings will be essential to assess how this leverage impacts the bottom line.